FY2020 · ended Dec 31, 2020 · Revenue $73.81M, -34.0% YoY · Filed Mar 13, 2023
Omeros Corp (OMER) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$116.2 million. As of Jun 30, 2026 it held $132.0 million in cash and investments and $73.3 million in total debt.
Revenue
$73.81M
-34.0% vs prior year
Net income (TTM)
$124.83M
+201.9% vs year-ago TTM
Operating cash flow (TTM)
$-68.67M
+42.2% vs year-ago TTM
Free cash flow (TTM)
$-68.73M
+42.2% vs year-ago TTM
EPS
$-0.05
-106.6% vs prior year
Dividend per share
None
Shares outstanding
72.00M
+23.5% vs prior year
Net cash
$58.66M
as of Jun 30, 2026
Operating margin
-212.6%
FY 2020
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OMER (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- WA
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1285819
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$122.8M | -$167.0M | -$164.5M | -$163.4M | -$173.6M |
| Net income | -$3.4M | -$156.8M | -$117.8M | $47.4M | $194.2M |
| Diluted EPS | -$0.05 | — | — | $0.76 | $3.12 |
| Operating cash flow | -$116.1M | -$148.8M | $74.7M | -$86.5M | -$109.7M |
| Free cash flow | -$116.2M | -$149.0M | $74.3M | -$86.6M | -$110.0M |
| Total assets | $325.6M | $277.1M | $378.3M | $591.0M | $419.3M |
| Stockholders' equity | -$121.2M | -$182.6M | -$25.0M | $85.7M | $23.8M |
| Cash and investments | $171.8M | $90.1M | $171.8M | $194.9M | $157.3M |
| Total debt | $82.0M | $184.3M | $213.2M | $342.0M | $347.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 30, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 13, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Other events
|
Jul 20, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Other events
|
Jul 6, 2026 | Jul 2, 2026 |
All 810 Omeros Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.